Pluri Inc. announced that its CDMO division (PluriCDMO?) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. PluriCDMO? will support Remedy Cell?s production team in the manufacturing of a clinical-grade Working Cell Bank (WCB) and GMP batches of Remedy Cell?s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a lethal, complex, progressive interstitial lung disorder with a median survival of 3.8 years.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.525 USD | -3.91% | +4.84% | +19.18% |
May. 02 | Pluri Inc. Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment | CI |
May. 02 | Pluri Inc. Announces Appointments to Its Scientific Advisory Board | CI |
1st Jan change | Capi. | |
---|---|---|
+19.18% | 30.99M | |
+21.54% | 47.9B | |
+46.56% | 41.42B | |
-2.68% | 40.7B | |
-6.20% | 28.92B | |
+10.73% | 25.55B | |
-21.73% | 19.27B | |
-1.54% | 12.15B | |
+30.66% | 12.14B | |
-0.87% | 11.99B |
- Stock Market
- Equities
- PLUR Stock
- News Pluri Inc.
- Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing